Access cutting-edge igm neuropathy treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.
Access igm neuropathy specialists in Boston at no cost
This study follows strict safety protocols and ethical guidelines
All study-related igm neuropathy treatment provided free
In this research study, is combining a new treatment acalabrutinib with a standard treatment, rituximab or other CD20 antibody, to determine whether this combination is safe and effective for participants with Immunoglobulin (Ig) M monoclonal gammopathy of undetermined significance ( IgM MGUS) or Waldenström macroglobulinemia WM related neuropathies. The names of the study drugs involved in this study are/is: * Acalabrutinib * Rituximab or similar CD20 antibody
Sponsor: Shayna Sarosiek, MD
Check if you qualify for this igm neuropathy clinical trial in Boston, MA
If you're searching for igm neuropathy treatment options in Boston, MA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced igm neuropathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.